Journalartikel
Autorenliste: Dimopoulos, Meletios A.; Kastritis, Efstathios; Owen, Roger G.; Kyle, Robert A.; Landgren, Ola; Morra, Enrica; Leleu, Xavier; Garcia-Sanz, Ramon; Munshi, Nikhil; Anderson, Kenneth C.; Terpos, Evangelos; Ghobrial, Irene M.; Morel, Pierre; Maloney, David; Rummel, Mathias; Leblond, Veronique; Advani, Ranjana H.; Gertz, Morie A.; Kyriakou, Charalampia; Thomas, Sheeba K.; Barlogie, Bart; Gregory, Stephanie A.; Kimby, Eva; Merlini, Giampaolo; Treon, Steven P.
Jahr der Veröffentlichung: 2014
Seiten: 1404-1411
Zeitschrift: Blood
Bandnummer: 124
Heftnummer: 9
ISSN: 0006-4971
eISSN: 1528-0020
Open Access Status: Green
DOI Link: https://doi.org/10.1182/blood-2014-03-565135
Verlag: American Society of Hematology (ASH Publications)
Abstract:
Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM(IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
Zitierstile
Harvard-Zitierstil: Dimopoulos, M., Kastritis, E., Owen, R., Kyle, R., Landgren, O., Morra, E., et al. (2014) Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus, Blood, 124(9), pp. 1404-1411. https://doi.org/10.1182/blood-2014-03-565135
APA-Zitierstil: Dimopoulos, M., Kastritis, E., Owen, R., Kyle, R., Landgren, O., Morra, E., Leleu, X., Garcia-Sanz, R., Munshi, N., Anderson, K., Terpos, E., Ghobrial, I., Morel, P., Maloney, D., Rummel, M., Leblond, V., Advani, R., Gertz, M., Kyriakou, C., ...Treon, S. (2014). Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 124(9), 1404-1411. https://doi.org/10.1182/blood-2014-03-565135
Schlagwörter
2ND INTERNATIONAL WORKSHOP; AL AMYLOIDOSIS; BORTEZOMIB-MELPHALAN-PREDNISONE; CLINICAL-TRIAL; IGM AMYLOIDOSIS; PANEL RECOMMENDATIONS; PHASE-II TRIAL; PRIMARY THERAPY; PROGNOSTIC SCORING SYSTEM
